We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Irinotecan and Other Agents in Upper Gastrointestinal and Genitourinary Tumors

  • Jaffer A. Ajani, MD
May 2, 2002
Volume: 
16
Issue: 
5
  • Ovarian Cancer

The 4th Investigators’ Workshop sponsored by The
University of Texas M. D. Anderson Cancer Center was held on July 25-29, 2001,
in Colorado Springs, Colorado. The purpose of these annual workshops has been to
review the latest data on new agents, with a particular focus on the broadly
used agent irinotecan (CPT-11, Camptosar).

Investigators from around the world were invited to present current research.
The forums were highly interactive and frank, thus allowing stimulation of new
ideas and directions. The meetings were more like a workshop rather than
didactic sessions. Six separate scientific sessions were held, and the
respective sessions covered colorectal carcinoma, upper
gastrointestinal/genitourinary carcinoma, lung carcinoma, and new combinations
and other tumor types.

In addition to stimulating research, another purpose of these workshops is to
develop enduring material for wider distribution to those who did not attend.
Thus, four publications are intended. This second volume is devoted to upper
gastrointestinal/genitourinary malignancies. Successive volumes will be devoted
to new combinations and other malignancies (volume 3) and lung malignancies
(volume 4). Last month, the first volume focused on colorectal
cancers
.

Gastric Carcinoma

In this volume, David Ilson and colleagues report on a phase I trial of
weekly irinotecan, cisplatin, and concurrent radiotherapy in patients with
locally advanced esophageal cancer—an aggressive cancer with a poor prognosis.
Among the 13 evaluable patients, there were 5 clinical complete responses (38%),
including 3 pathologic complete responses in 10 patients undergoing surgery
(30%). These data indicate that full doses of weekly irinotecan (65 mg/m²) and
cisplatin (30 mg/m²) can be combined safely with concurrent radiotherapy in
patients with locally advanced esophageal cancer.

Gastric carcinoma continues to be a significant health problem despite its
decreasing incidence, and it remains the second most common malignant disorder
in the world. In our article, my colleagues and I summarize our data from a
phase II study that assessed the response rate and toxicity profile of the
irinotecan/cisplatin combination administered weekly to patients who have had at
least one previous chemotherapy for advanced adenocarcinoma of the stomach or
gastroesophageal junction. A 29% response rate was achieved in the study.
Modifications in doses and schedule are warranted to increase the tolerability
of the regimen in further investigation.

Pancreatic Cancer

Pages

  • 1
  • 2
  • 3
  • next ›
  • last »

Related Articles

  • Promising Personalized Ovarian Cancer Vaccine Induces Immune Responses
  • FDA Approves Rucaparib for Recurrent Ovarian Cancer Maintenance Therapy
  • PARP-7 Amplification Mutations Linked to Prolonged Survival in Ovarian Cancer
  • Trial Participation May Offset Disparities in Ovarian Cancer Care
  • Despite Evolving Treatment for Ovarian Cancer, Late Diagnosis Remains a Challenge

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.